Navigation Links
Co-sponsors highlight important research to be presented at the 2013 Breast Cancer Symposium
Date:9/6/2013

SAN FRANSISCO, CA Five additional studies of note are among those that will be presented at the 2013 Breast Cancer Symposium, taking place September 7-9, 2013 at the San Francisco Marriott Marquis in San Francisco, California. Two studies examine cognitive function in women who undergo treatment for early-stage breast cancer; a third evaluates impact of tumor genotyping on clinical trial enrollment; and the final two evaluate the outcomes of different treatment approaches.

Saturday, September 7 Presentations

Abstract #48:
Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy (NCT) and analysis of survival outcome.

General Poster Session A
Saturday, September 7, 2013, 11:30 AM 1:00 PM PST
Saturday, September 7, 2013, 4:30 PM 6:00 PM PST
Golden Gate Hall

Napa Parinyanitikul, MD
The University of Texas MD Anderson Cancer Center
Houston, TX

Abstract # 55:
Ten-year outcomes of accelerated partial breast irradiation compared with whole breast irradiation: A matched-pair analysis.

Poster Discussion A
Saturday, September 7, 2013, 4:00 PM 4:20 PM PST
Yerba Buena Ballroom, Salon 8

Jessica Wobb, MD
Oakland University William Beaumont School of
Medicine, Beaumont Cancer Institute
Royal Oak, MI

Sunday, September 8 Presentations

Abstract # 105:
Prospective study of cognitive function (cog fcn) in women with early-stage breast cancer (BC): Relationship between perceived and measurable cognitive deficits.

Poster Discussion B
Sunday, September 8, 2013, 3:00 PM 3:20 PM PST
Yerba Buena Ballroom, Salon 8

Lara Heflin, PhD
New Mexico Highlands University
Las Vegas, NM

Abstract # 104:
Prospective study of cognitive function (cog fcn) in women with early-stage breast cancer (ESBC): Predictors of cognitive decline.

Poster Discussion B
Sunday, September 8, 2013, 3:00 PM 3:20 PM PST
Yerba Buena Ballroom, Salon 8

Hope S. Rugo, MD
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Abstract # 145:
Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review.

Poster Discussion B
Sunday, September 8, 2013, 4:00 PM 4:20 PM PST
Yerba Buena Ballroom, Salon 8

Aditya Bardia, MD
Massachusetts General Hospital,
Harvard Medical School
Boston, MA


'/>"/>

Contact: Kate Blackburn
Kate.Blackburn@asco.org
571-483-1379
American Society of Clinical Oncology
Source:Eurekalert

Related medicine news :

1. PhUSE Co-sponsors the Annual FDA/PhUSE Computational Science Symposium, in Silver Spring Maryland, USA, March 18th-19th 2013
2. Presidential keynote address and new research highlights from the American Society of Pediatric Otolaryngology meeting
3. Scientific session and new research highlights
4. Triple negative breast cancer symposium highlights current advances
5. Study highlights need for coordination of care in stage 2 and 3 rectal cancer treatment
6. Clinical news alert: Journal of the American Academy of Orthopaedic Surgeons May highlights
7. New influenza virus from seals highlights the risks of pandemic flu from animals
8. JAAOS study highlights success of nerve transfer surgery
9. Researchers highlight treatment, research needs for homeless families
10. Deadly outbreak of West Nile virus highlights urgent need for more research, funding
11. AAO-HNSF 2012 new oral research daily highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... ... Miami native and local periodontist Dr. John Paul Gallardo is celebrating ... 1991 that this journey would have taken me into so many learning experiences both ... has pioneered implant dentistry innovation, evolving into an internationally recognized leader in the industry. ...
(Date:4/26/2017)... , ... April 26, 2017 , ... ... today launched a unique website ( CRISPRCas.pioneer.com ) that demonstrates how this advanced ... farmers produce more and better food, with fewer resources. It highlights the business’ ...
(Date:4/26/2017)... Doylestown, Pa. (PRWEB) , ... ... ... Solutions division, which provides an agile ecosystem and domain expertise for sponsors ... end-to-end, configurable randomization and trial supply management (RTSM) software platform. Bioclinica ...
(Date:4/25/2017)... ... April 25, 2017 , ... Bellus Medical, a ... first in a new class of photodynamic cosmetics (PDC). , Allumera® is the ... reduce outward signs of aging, and minimize the appearance of pores – all ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... agreement to be the preferred physical therapy provider for Derby City CrossFit, effective ... Derby City CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/19/2017)... CRH) (NYSE MKT: CRHM) (the "Company"), announces that it will participate ... the Sheraton Hotel in Toronto, Ontario . ... is scheduled to present on Tuesday, May 2 at 10:00 am. ... the Board, Tony Holler will also attend the event. ... For more details about the ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
Breaking Medicine Technology: